Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- RAC
- Ann: Race releases complete cardio-protection data & video
Ann: Race releases complete cardio-protection data & video, page-228
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.75 |
Change
-0.040(2.23%) |
Mkt cap ! $297.9M |
Open | High | Low | Value | Volume |
$1.79 | $1.79 | $1.72 | $146.2K | 83.61K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2901 | $1.73 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.75 | 994 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2901 | 1.730 |
1 | 644 | 1.725 |
2 | 4039 | 1.720 |
1 | 538 | 1.715 |
1 | 1281 | 1.710 |
Price($) | Vol. | No. |
---|---|---|
1.750 | 994 | 1 |
1.760 | 257 | 1 |
1.765 | 5000 | 1 |
1.770 | 30 | 1 |
1.780 | 5000 | 1 |
Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
Last
$1.74 |
  |
Change
-0.040 ( 1.51 %) |
|||
Open | High | Low | Volume | ||
$1.76 | $1.77 | $1.72 | 23546 | ||
Last updated 15.56pm 17/06/2024 ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online